Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months
Ee Vien Low, Kalaiarasu M. Peariasamy(Ministry of Health), Shahanizan Mohd Zin(Ministry of Health), Hazlina Yahaya(Ministry of Health), Sheamini Sivasampu(Ministry of Health), Boon Hwa Tng(Ministry of Health), Maheshwara Rao Appannan(Ministry of Health), Jing Lian Suah(Ministry of Health), Faizah Muhamad Zin(Ministry of Health), Thevesh Thevananthan(Ministry of Health), Peter Seah Keng Tok(Ministry of Health), Masliyana Husin(Ministry of Health)
Cited by 24
Related Papers
Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis
|The Lancet Digital Health|2022|178
Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
|The Lancet Regional Health - Western Pacific|2020|132
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
|JAMA Internal Medicine|2022|105
Influence of Population Density for COVID-19 Spread in Malaysia: An Ecological Study
|International Journal of Environmental Research and Public Health|2021|85
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
|International Journal of Infectious Diseases|2022|79